Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

Latest move to cut funding for vaccines is not down to US health secretary. It is part of Trump’s wider war on science.

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Federal vaccine policy changes under RFK Jr. have some concerned health insurance will not cover COVID shots. A bill in NY ...

COVID vaccines, including the new non-mRNA product Novavax, are safe and effective and decrease the burden of illness and ...